New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:16 EDTBAX, HSPBaxter rationing supplies of nitroglycerin since January, NY Times says
The New York Times reports that Baxter (BAX) has been unable to keep up with demand for injectable nitroglycerin since Hospira (HSP) and American Regent stopped selling their products due to manufacturing problems and delays. The company has been rationing supplies off the drug since January. Reference Link
News For BAX;HSP From The Last 14 Days
Check below for free stories on BAX;HSP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
11:50 EDTHSPJudge rules generic Precedex FDA approval postponed, WSJ says
Subscribe for More Information
August 19, 2014
16:33 EDTBAXBaxter to expand Alabama facility to increase dialyzers production
Subscribe for More Information
09:09 EDTHSPHospira discloses it filed lawsuit against FDA regarding Precedex
Subscribe for More Information
09:08 EDTHSPHospira backs FY14 EPS $2.30-$2.50, consensus $2.43
August 18, 2014
11:41 EDTHSPCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 14, 2014
08:07 EDTBAXKamada sees FY14 revenue $70M-$72M, consensus $75.4M
Kamada (KMDA) expects FY14 revenue $70M-$72M, with revenue from its Distribution Segment projected to be between $25M-$26M and revenue from its Proprietary Products Segment to be between $45M-$47M. The company notes that U.S. revenues from the agreement with Baxter (BAX) remain on track.
August 7, 2014
09:03 EDTBAXBaxter opens biologics facility in Singapore
Baxter International announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite. The current suite supports the processing of ADVATE.The second suite will initially process RIXUBIS, a recombinant factor IX protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval. The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of ADVATE2. This allows the facility to process and supply ADVATE to the European Union, Iceland and Norway. The biologics facility in Singapore currently employs more than 400 production staff and expects to reach 450 by 2015 to support the second processing suite.
August 6, 2014
06:23 EDTHSPMitsubishi UFJ to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use